Squarepoint Ops LLC Has $1.95 Million Stake in Genmab A/S Sponsored ADR $GMAB

Squarepoint Ops LLC increased its stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 636.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 94,233 shares of the company’s stock after buying an additional 81,434 shares during the quarter. Squarepoint Ops LLC’s holdings in Genmab A/S were worth $1,947,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Captrust Financial Advisors raised its holdings in Genmab A/S by 2.4% in the 2nd quarter. Captrust Financial Advisors now owns 22,442 shares of the company’s stock valued at $464,000 after acquiring an additional 526 shares in the last quarter. Rhumbline Advisers increased its position in shares of Genmab A/S by 3.2% in the first quarter. Rhumbline Advisers now owns 16,956 shares of the company’s stock worth $332,000 after purchasing an additional 532 shares during the period. CWM LLC increased its position in shares of Genmab A/S by 50.5% in the second quarter. CWM LLC now owns 1,797 shares of the company’s stock worth $37,000 after purchasing an additional 603 shares during the period. Yousif Capital Management LLC raised its stake in Genmab A/S by 7.8% in the second quarter. Yousif Capital Management LLC now owns 10,943 shares of the company’s stock valued at $226,000 after purchasing an additional 790 shares in the last quarter. Finally, Park Avenue Securities LLC lifted its position in Genmab A/S by 5.9% during the second quarter. Park Avenue Securities LLC now owns 14,940 shares of the company’s stock worth $309,000 after purchasing an additional 832 shares during the period. Institutional investors own 7.07% of the company’s stock.

Wall Street Analyst Weigh In

GMAB has been the topic of several recent analyst reports. Guggenheim raised shares of Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 target price on the stock in a report on Tuesday, September 23rd. Truist Financial reissued a “buy” rating and issued a $48.00 price objective (down from $49.00) on shares of Genmab A/S in a research note on Thursday, November 6th. Johnson Rice restated a “buy” rating on shares of Genmab A/S in a research note on Monday, October 27th. HC Wainwright raised their target price on Genmab A/S from $40.00 to $41.00 and gave the company a “buy” rating in a report on Monday, November 10th. Finally, Wall Street Zen upgraded Genmab A/S from a “hold” rating to a “buy” rating in a research note on Saturday, November 22nd. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $39.75.

Genmab A/S Trading Down 0.7%

Genmab A/S stock opened at $31.50 on Friday. The stock has a 50-day moving average price of $30.75 and a two-hundred day moving average price of $26.57. Genmab A/S Sponsored ADR has a 12 month low of $17.24 and a 12 month high of $33.65. The company has a market capitalization of $20.23 billion, a PE ratio of 13.40, a P/E/G ratio of 1.65 and a beta of 0.90.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.17. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $975.40 million. Genmab A/S had a return on equity of 23.98% and a net margin of 41.36%. As a group, analysts predict that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.